Myomo (MYO) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MYO Myomo Inc MYO
57 GF Score
Price $0.95
GF Value $3.14
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Myomo 5-Year Yield-on-Cost %?

Myomo MYO -9.51% 57 5-Year Yield-on-Cost % is 0.00 as of Jul. 18, 2026. GuruFocus rates MYO with a GF Score™ of 57/100 and a GF Value™ of $3.14 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 325 Medical Devices & Instruments companies, Myomo ranks worse than 307692% on this metric.

Myomo's yield on cost for the quarter that ended in Mar. 2026 was 0.00.


The historical rank and industry rank for Myomo's 5-Year Yield-on-Cost % or its related term are showing as below:



MYO's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.34
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Myomo  (AMEX:MYO) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Myomo 5-Year Yield-on-Cost % Related Terms


MYO vs FOFA, ELUT, PAVM: 5-Year Yield-on-Cost % Comparison

For the Medical Devices subindustry, Myomo's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Myomo 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Myomo's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Myomo's 5-Year Yield-on-Cost % falls into.


MYO
57GF Score
Myomo Inc MYO
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Myomo 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Myomo is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Myomo (MYO) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 18, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Myomo and its competitors. According to the industry distribution chart, Myomo ranks #999999 out of 325 companies in the Medical Devices & Instruments industry.
Is Myomo's 5-Year Yield-on-Cost % too high?
Myomo's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Myomo ranks #999999 out of 325 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Myomo has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myomo's 5-Year Yield-on-Cost % compare to FOFA and ELUT?
According to the Medical Devices & Instruments industry distribution chart, Myomo ranks #999999 out of 325 companies for 5-Year Yield-on-Cost %. This places Myomo in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.34. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.34, based on 325 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Myomo and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Myomo's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myomo stock overvalued right now?
Based on GuruFocus' analysis, Myomo (MYO) is currently considered Possible Value Trap. The stock's GF Value™ is $3.14, compared to a current price of $0.95 — trading 69.7% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Myomo's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Myomo (MYO), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Myomo (MYO) Overvalued in 2026?

Based on GuruFocus' analysis, Myomo stock appears to be undervalued. The current stock price of $0.95 is trading 69.7% below its estimated GF Value™ of $3.14. GuruFocus considers Myomo to be Possible Value Trap.

Key valuation signals for MYO:

  • 5-Year Yield-on-Cost %: 0.00
  • GF Value™: $3.14 vs. price of $0.95 (69.7% below fair value)
  • GF Score™: 57/100 with 5 warning signs

No single metric tells the full story. See the MYO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Myomo Business Description

Other Exchanges 0M61:Germany
Address 45 Blue Sky Drive, Suite 101, Burlington, MA, USA, 01803
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.
57GF Score

Get the complete analysis for MYO

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.95
Price
$3.14
GF Value